CN201194855Y - Medicament elution coronary-artery stent - Google Patents
Medicament elution coronary-artery stent Download PDFInfo
- Publication number
- CN201194855Y CN201194855Y CNU2007201907399U CN200720190739U CN201194855Y CN 201194855 Y CN201194855 Y CN 201194855Y CN U2007201907399 U CNU2007201907399 U CN U2007201907399U CN 200720190739 U CN200720190739 U CN 200720190739U CN 201194855 Y CN201194855 Y CN 201194855Y
- Authority
- CN
- China
- Prior art keywords
- medicine
- drug
- coronary artery
- artery stent
- eluting coronary
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Images
Landscapes
- Materials For Medical Uses (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The utility model provides a medicine elutropic coronary bracket which comprises a basal body. The medicine elutropic coronary bracket is characterized in that a compact layer and a loose layer are included, the compact layer and the loose layer are distributed on the basal body in sequence. Through the compact layer and the loose layer which have faviform structure and medicine microballoons contained in the faviform structures, the medicine elutropic coronary bracket avoids many problems existing in the prior art. Moreover, the thickness of the surface of the faviform structures composed of the compact layer and the loose layer at the surface of the basal body of the bracket provided by the utility model is only 50-120 micrometers, which does not affect the physical and mechanical properties including supporting strength of the basal body of the bracket.
Description
Technical field
This utility model relates to the medical skill for the treatment of cardiovascular disease, more specifically relates to a kind of drug-eluting coronary artery stent (DES) structure.
Background technology
Drug-eluting coronary artery stent, be called for short bracket for eluting medicament, through a large amount of clinical uses, the result shows: it is determined in curative effect aspect the treatment coronary heart disease (coronary stenosis), it can significantly reduce behind the stenting neointimal hyperplasia and late period coronary lumen and lose, thereby interior coronary restenosis of reduction sections and target lesion be myocardial revascularization rate (TLR) once more, and its final incidence rate that reduces serious and adverse events (MACE) makes one of its main means of coronary heart disease that become present treatment coronary stenosis both at home and abroad.But extensive use along with DES, the safety of DES, the interior thrombosis (LAST:Late Stent Thrombosis) of particularly tardy support in late period is one of problem of numerous scholars and clinician's concern always, wherein, definition generally is meant the thrombosis that occurs after 1 year behind the stenting for LAST.
Find that (BMS) compares with bare metal stent in a large amount of clinical researches, the stent strut ratio of DES postoperative new intima area and endothelialization significantly reduces.Statistical information shows that the BMS postoperative had the stent strut more than 84% to be covered by newborn endothelium in 2 months, and the DES postoperative only had 45% stent strut to be covered by newborn endothelium in 2 months, and the incomplete state of this endothelialization can extend to postoperative more than 40 months.
Usually, the three big key elements of composition DES are: the metal rack of the delivery platform of (1) medicine--unlike material and different structure or non-metal frame (not being used for clinical at present as yet).(2) the ＂ warehouse ＂ of medicine, can carry medicine, and can slowly discharge the polymer [being high polymer: Polymer] of medicine in vivo, that uses at present has a PEG (Polyethylene Glycol), PLA (polylactic acid), PCL (pla-pcl), PBMA (polymethylacrylic acid fourth fat), PEMA (polyethyl methacrylate), PEVA (polyethylene vinyl acetate resin), PU (polyurethane), SIR (organic silicon rubber), PVP (polyvinyl pyrrolidone) and PC (polyphosphoric acid choline) etc.What have degrades with medicament elution (release), and what have can not degrade and be attached on the support for a long time.(3) medicine: the two big classes that mainly contain that enter clinical practice at present: a class is an immunosuppressant, for example rapamycin and derivant thereof (tacrolimus FK 506, and everolimus, ABT578 and mycophenolic acid); Another kind of is for example paclitaxel of antiproliferative agents, defence line rhzomorph D, tyrosine-kinase enzyme inhibitor, angiopeptin, Bastimastac, the anti-mononucleotide of translating of C-myc, perlecan and synthesis type CDK depressant Flaropiridol.In the middle of them, the existing commodity of rapamycin and paclitaxel come into the market.In addition, the medicine of studying has the tyrosine kinase receptor depressant, anti-inflammatory agent (for example 17-hydroxy-11-dehydrocorticosterone-dexamethasone) and the vitamin with antioxidation, Statins fat regulation medicine etc.
Adopt at present the DES of prior art manufacturing to be used widely, as being gone on the market by drugs approved by FDA, and abroad, domestic clinical in extensive use be the BX Velocity of Johnson Co. (Cordis)
TMThe rapamycin FirebirdTM.Employed medicine be rapamycin (Sirolimus, commodity are called Rapamusyon) this be class macrolide medicine, chemical constitution and cyclosporin A, FK506 is similar, such medical instrument has antibiotic and effect cell proliferation.Such medicine, caused rejection when being mainly used in prevention of organ transplant clinically at present, the mechanism of action is to stop the transformation of cell from the G1 phase to the S phase, the breeding of blocking t cell is bred thereby stop mRNA to transcribe with PCNA.
The example of another DES is also gone on the market by drugs approved by FDA, and that use in clinical is the paclitaxel FirebirdTM TAXUS that the boston, u.s.a scientific company is produced, different with rapamycin is, paclitaxel extract from the Pacific yew tree, it is two obedient compounds of skeleton that 20 carbon atoms are arranged, and is the class natural anti-cancer drugs.Its mechanism of action is the mitosis that stops cell, and stabilize microtubules stops the migration of cell and the transmission of signal, and it has all shown following function in the research in vivo and in vitro: stop neointima proliferation, stop the breeding and the migration of smooth muscle cell.
Among the aforementioned existing DES that uses in clinical, medicine is to be dispersed in the polymer, and polymer is used the whole bag of tricks and is coated on the rack surface securely.What if polymer can not degradation-type, then after being released, medicine still covers rack surface securely; And if polymer degradable type then little by little is low-molecular-weight thing (fragment) in the d/d while of medicine and enters blood and be eliminated.
DES is very welcome and effective in clinical, and Just because of this, its weak point just causes clinician and medical apparatus and instruments producer's very big concern, and main deficiency is meant: LAST and the bad problem of support in late period adherent (blood vessel).Internationally famous cardiovascular specialist, U.S. professor Vermani points out from pathologic angle, in the LAST factors, the existence of polymer and support endothelialization postpone, late period, support was adherent bad, and the high sensitization (material that degradable polymer generates in degraded causes) of polymer initiation and inflammatory reaction etc. all have direct relation.
In sum, the primary condition as good DES is: on the coronary artery bracket energy must be arranged
Slow ReleaseMedicine, preventing when the treatment coronary stenosis part, the support expansion strutted and due to illness became and narrow tunica intima originally, made the emergency reaction of arterial intima produce neointimal hyperplasia.And optimal state is with the arteria coronaria neointimal hyperplasia medicine that can prevent to cause in the stenting operation on support, this medicine play prevent the neointimal hyperplasia effect in, do not hinder on the rack surface of inserting inner membrance again and normally climb life, form rack surface ＂ tunica intima ＂.
In brief, the scheme that existing drug-eluting coronary artery stent DES generally adopts is: be coated with the polymer layer on support matrix top layer, include medicine on this polymer.This scheme is the following problem of ubiquity in use: 1, the DES of this coating polymer layer has relatively poor bio-compatible performance, and the long period is easy to generate thrombosis in blood vessel; 2, only be provided with the polymer layer on the top layer of support matrix, be difficult to slowly discharge in a long time medicine, and the support matrix (the support matrix that perhaps has the polymer layer) that has discharged behind the medicine will hinder the endothelialization of rack surface blood vessel, thereby causes LAST and the adherent bad phenomenon of support; 3, the polymer layer of drug loading also can cause high sensitization and inflammatory reaction; Or the like.
The utility model content
The purpose of this utility model is promptly providing a kind of drug-eluting coronary artery stent, its compacted zone and weaker zone by having alveolate texture, and/or in alveolate texture, be equipped with medicine microspheres, thereby avoid the potential problems that exist in the above-mentioned prior art.And the alveolate texture surface bed thickness that the support matrix surface compacted zone that provides of this utility model and weaker zone are formed only is 50-120um, and it does not influence the physical and mechanical properties that this support matrix comprises support strength.
This utility model provides a kind of drug-eluting coronary artery stent, includes matrix, and it focuses on: this drug-eluting coronary artery stent also includes compacted zone and weaker zone, and this compacted zone and weaker zone are distributed on the matrix successively.
This compacted zone is the metal oxide ceramic layer in fine and closely woven aperture.This weaker zone is wide-aperture metal oxide ceramic layer.More specifically, described metal oxide ceramic layer is a honeycomb texture.
In the described honeycomb texture metal oxide ceramic layer, be equipped with the microsphere of encapsulation medicine.
Described medicine microspheres includes medicine and coating material.
Described coating material is a degradable substance, for example following material a kind of or several: chitin, chitosan, alginate.
This drug-eluting coronary artery stent also includes biodegradable layers.
Therefore, this utility model is compared with above-mentioned known technology, the utlity model has following beneficial effect:
1, existing commercially available, the DES bio-compatible performance of Ying Yonging is undesirable clinically, in coronary artery after the long period, still have larger proportion the arteria coronaria tunica intima to occur and form imperfect reaching and the disjunct phenomenon generation of arteria coronaria blood vessel wall, directly cause support to insert thrombosis symptom generation in the arteria coronaria blood vessel in late period of back.And the newtype drug eluting coronary artery stent that this utility model provides, even do not possessing good bio-compatible performance with medicine (or drug release finishes the back) yet, shown that in animal experiment its long period in blood vessel does not produce thrombosis (for example insert in the arteria coronaria to the very similar pig of people's arteria coronaria, produce blood coagulation and blood vessel blockage through all seeing in 13 weeks).
2, the nondegradable polymer layer Chinese medicine among the existing DES is to discharge medicine by drug release mechanism, rather than presses medicine controlled releasing mechanism release medicine.For this reason, the prominent phenomenon (" explosion " phenomenon) and can not the relative constant of medicine ground release in longer a period of time released of medicine is arranged.In addition, non-degradation-type polymer is after the medicament slow release that it comprises finishes, and this polymer (containing the small amount of residual medicine) just becomes foreign body and hinders support matrix surface blood vessel endotheliumization, thereby causes LAST and the adherent bad phenomenon of support to take place.And this utility model is by being contained in medicine microspheres in the honeycomb texture of compacted zone and weaker zone, make the release of medicine in blood more evenly, slowly, thereby reduce the generation of medicine explosion release phenomenon, and outside being arranged so that the controlled release of medicine of biodegradable layers and more near desirable; In addition, after breaking away from the position of honeycomb when the medicine microspheres degraded, this cellular position becomes " foothold " of normal endothelial tissue growth again, helps the arteria coronaria endothelial tissue and climbs living, growth, promotes to insert the surperficial complete blood vessel endotheliumization of coronary artery bracket.The blood vessel endotheliumization that rack surface is complete just can overcome adherent problem such as bad of LAST that the DES of current clinical use occurs and support late period.
3, the degradable polymer layer among the existing DES, usually with the generation that has zest " fragment ", it may cause high sensitization and inflammatory reaction when polymer is degraded.And the coating material of the employed medicine microspheres of this utility model is polysaccharide chemical compounds such as chitin, chitosan, alginate.And chitosan itself just has functions such as antibiotic, antiinflammatory, be performance comparatively comprehensively, the biomaterial of good biocompatibility.
Generally speaking, adopt biological safety very high, biodegradable material is coating material, with the microspheres form drug loading, to have cellular void structure metal oxide ceramic layer surface on the support matrix, absorption, adhesion encapsulation the microsphere of medicine, and the complete thin film that the microsphere skin is made up of one deck degradation material is coating.The drug-eluting coronary artery stent of this version is climbed life for normal arteria coronaria blood vessel endothelium is organized in the rack surface of inserting again when slow (control) discharges medicine, promote the complete blood vessel endotheliumization of inserting in coronary artery bracket surface.Thereby prevent or effectively reduce that LAST that the DES of current clinical use exists and support and blood vessel late period, adherent phenomenon such as bad was useful point of the present utility model and distinctive feature.
Description of drawings
Fig. 1 is the generalized section of the described drug-eluting coronary artery stent of this utility model preferred embodiment.
The specific embodiment
Characteristics of the present utility model can be consulted the detailed description of the graphic and embodiment of this case and obtained to be well understood to.
Drug-eluting coronary artery stent described in the utility model adopts the electrochemical method manufacturing, particularly is meant to adopt the method for differential arc oxidation to handle.At first provide the matrix of metal coronary artery bracket, as titanium alloy support (for example titanium alloys such as Nitinol, Ti6Al4V and Ti-6Al-7Nb are the support matrix that raw material is made).The optional commercially available two great electronics (SHEKONIC of micro arc oxidation treatment device that adopts
TM) WWL-LDX series lines sexual intercourse stream power supply (as 20KW stream pulse mao power source) etc.This device has following main points: a, dc source, and its output voltage, output current intensity are adjustable continuously; B, electrolysis bath are made up of rustless steel, and cell wall is as negative electrode; C, heater heat the electrolyte in the electrolysis bath; D, agitator make the electrolyte homogeneous heating; E, anode, the matrix of metal coronary artery bracket is as anode; F, electrolyte: be loaded in the electrolysis bath, quantity gets final product to flood negative electrode, and the prescription of electrolyte is as follows: adding concentration in the distilled water of every 400ml is the (CH of 0.2mol/L-0.6mol/L
3COO)
2CaH
2O, concentration are the NaH of 0.02mol/L-0.06mol/L
2PO
4Each 45ml-65ml.After stirring,, the matrix of metal rack is put into 1-12 minute electrolyte persistent period get final product the logical alternating current power supply that goes up 380V of micro arc oxidation treatment device.This moment, the acidity-basicity ph value of mixed solution was 6.
Through above-mentioned processing, promptly obtain this utility model, Fig. 1 is the generalized section of the described drug-eluting coronary artery stent 1 of this preferred embodiment.As shown in the figure, this utility model drug-eluting coronary artery stent 1 includes matrix 11, and it focuses on: this drug-eluting coronary artery stent 1 also includes compacted zone 12 and weaker zone 13, and this compacted zone 12 and weaker zone 13 are distributed on the matrix 11 successively.This compacted zone 12 and weaker zone 13 are metal oxide ceramic layer, and metal oxide ceramic layer is the porous honeycomb texture that includes hole 14, and this hole 14 is not of uniform size, rounded.In an embodiment as shown in Figure 1, the bore dia in bigger hole 14 is about 5 microns, and the outermost top layer is a weaker zone, and its thickness is about 63 microns, is compacted zone 12 between weaker zone 13 and the matrix 11, and the thickness of this compacted zone 12 and weaker zone 13 is about 82 microns.Present embodiment is directly implanted the femoral artery of Canis familiaris L. and do not found the blood coagulation phenomenon half a year, and present embodiment is directly implanted the arteria coronaria of pig, blood coagulation and blood vessel blockage do not take place in 13 weeks.
Adopting above-mentioned processing to obtain the support matrix surface is cellular metal oxide ceramic layer, and this metal oxide ceramic layer main chemical compositions is titanium dioxide (TiO
2), it is a kind of biomaterial with good biocompatibility, it does not cause the generation of thrombosis in blood, do not hinder the blood vessel endothelium tissue growth, it is extremely stable chemical compound simultaneously, do not dissolve chemical element to blood, the thrombosis of so just having avoided support parent metal material to cause produce and the support matrix in some dissolves in the problem of the medium generation of blood to the deleterious element of tissue (for example vanadium (V) etc.).
After making drug-eluting coronary artery stent, introduce below and make medicine microspheres.
The described medicine microspheres of present patent application embodiment adopts biodegradable, and catabolite not to be with irritating natural many (gathering) saccharide biomaterials such as acid, alkali be pharmaceutical carrier.This carrier with microspheres form with the medicine encapsulation wherein, and microsphere combines with above-mentioned support after treatment (being the described drug-eluting coronary artery stent of this utility model embodiment) with the external diameter of nanometer range, discharge the outgrowth medicine of endothelial tissue that contain in the medicine microspheres, anti-angiogenic stably, lentamente to reach the arteria coronaria medium-height trestle, reach the good purpose of clinical therapeutic efficacy of drug-eluting coronary artery stent.
The cyst material of encapsulation medicine microspheres, this cyst material can be selected from chitin, chitosan, alginate etc., the following examples are that example describes with the chitosan.
Encapsulation medicine microspheres preparation method:
According to the medicine that is adopted is water solublity or fat-soluble character, microsphere cyst material and medicine are under abundant stirring, fierce blended condition, formed o/w (oil-in-water), w/o (Water-In-Oil) and w/o/w[water bag (Water-In-Oil)] etc. the emulsion form, formed microsphere through after microsphere makeup amount----high-speed stirred or the phaco device emulsifying.Make the microsphere cyst material crosslinked by adding cross-linking agent (as glutaraldehyde etc.) again, reach have respective strengths, corresponding release medicine speed (as slow release or controlled release) and the purpose that the pastille microsphere is separated from the solution of reaction.
Embodiment 1
300 milligrams of medicine rapamycins (Rapamycin) (be dissolved in and form 10% rapamycin acetone (Acetone) solution in the acetone) are injected in 300 milliliters of chitosan acidic aqueous solutions.The shared weight percent of each material is a chitosan 3% in this solution; Acetic acid 2%; Sodium chloride 2%; Distilled water 93%.(wherein chitosan is the medicine microspheres coating material, and acetic acid aqueous solution is the solvent of chitosan, and sodium chloride plays and promotes the dissolved better short molten effect of chitosan) makes to obtain
The solution of medicine/chitosan=12%-18%.
The gram emulsifying agent---the liquid paraffin of sorbitan sesquioleate (Sorbitan Sesquioleate, Arlacel 83)/ether mixed liquor 3-5ml mixes with containing 0.85 with above-mentioned chitosan acidic aqueous solution.This mixed liquor is that its composition weight ratio of solvent of emulsifying agent is
White oil/ether=35 milliliter/25 milliliters.
Liquid high-speed stirred under 2000 rev/mins of rotating speeds that will contain chitosan acidic aqueous solution, emulsifying agent, medicine, after being emulsified into the w/o emulsion, 10 milliliters of the toluene solutions (wherein ratio is that 5 gram glutaraldehydes are dissolved in 95 milliliters of toluene) that add the cross-linking agent glutaraldehyde again, continue to stir 0.5-1.0 hour, make microsphere further crosslinked.Obtain the medicine carrying microballoons of diameter between 45～300nm at last, through centrifugalize, distilled water wash promptly gets medicine microspheres to neutral after the drying.
Though the glutaraldehyde cross-linking agent is difficult to wash clean, product haemolysis degree is more much lower than the linear chitosan molecule of not using glutaraldehyde cross-linking, shows that the biocompatibility of the described medicine microspheres of present embodiment is better than linear chitosan.
Embodiment 2
200 milligrams of medicine rapamycins (Rapamycin) (be dissolved in and form 1% rapamycin acetone (Acetone) solution in the acetone) are injected in 250 milliliters of chitosan acidic aqueous solutions.The shared weight percent of each material is a chitosan 2% in this acid solution; Acetic acid 1%; Distilled water 97%.(wherein chitosan is the medicine microspheres coating material, and acetic acid aqueous solution is the solvent of chitosan) makes to obtain
The solution of medicine/chitosan=13%-17%.
With mass concentration is that sodium tripolyphosphate (TPP) aqueous solution of 0.45 milligram-1.0 mg/ml is under the high-speed stirred of 2000 rev/mins of rotating speeds, slowly be added drop-wise in the above-mentioned pastille chitosan acetic acid solution, and make that the chitosan mass concentration is 0.5 milligram-1.0 mg/ml in the solution, the mass ratio that drips quantity and be pastille chitosan acetic acid solution and sodium tripolyphosphate solution is 5:1-10:1.Control reactant liquor acid-base value (pH value) is 3.5-6.5.After dripping end, continue to stir 0.5-1.0 hour.Promptly obtain the pastille microsphere of 500nm-5um.This product through centrifugalize,, is handled through lyophilizing to neutral with the distilled water wash microsphere again, promptly obtained finished product pastille microsphere.
This is to plant without organic solvent, helps keeping the method for pharmaceutical properties (especially active medicine) can prepare the particle diameter (diameter of micro ball) of medicine microspheres below 10um with this method.
Above-mentioned precipitant commonly used has phosphate, triphosphate etc.
After making medicine microspheres by said method, below this medicine microspheres is positioned in the hole on the drug-eluting coronary artery stent and (mainly concentrates in the hole on surface), specifically can take Electrostatic Absorption to stick together method or vacuum construction from part or any other method, the microsphere of medicine will be loaded with, dosage by clinical requirement makes it enter drug-eluting coronary artery stent, it is adsorbed sticks together at rack surface.
To handle once more through the drug-eluting coronary artery stent surface of the medicine carrying after the above-mentioned processing, make the Biodegradable material identical or different, will inlay the medicine microspheres that is attached in the rack surface hole and wrap a skim with the microsphere coating material with spraying or dipping process.Like this, the medicine of medicine microspheres encapsulation can be discharged equably after entering arteria coronaria, reduce the generation of medicine explosion release phenomenon, thereby reach purpose near the ideal control drug release.
The glutinous microsphere of embedding can prevent or reduce in stenting the loss that medicine carrying microballoons comes off when contacting with narrow arteria coronaria owing to by being wrapped a skim, form an integral body on the drug-eluting coronary artery stent in addition.
This covers assembly technology, not only can make two-sided or each side of support be covered with a skim, also can make a rack surface that only contacts with the arteria coronaria inner membrance be covered with a skim, and the mobile surface of support opposite side blood supply liquid is by overlay film, this technology is kind of a very special coating technique.
Behind above-mentioned coating technique, the newtype drug eluting coronary artery stent has just prepared successfully.Also will experience conventional packing, give technological processes such as assembling, sterilization, storing as commodity, thereby come into the market.
The described drug-eluting coronary artery stent of present embodiment had both been avoided the shortcoming of existing DES, can strengthen the advantage that requires drug-eluting coronary artery stent to possess in clinical again.Even the technical scheme of present embodiment makes drug-eluting coronary artery stent also not possess good bio-compatible performance with medicine, in animal experiment, demonstrate it can be in blood vessel [for example the arteria coronaria of pig--13 weeks did not all produce blood coagulation and blood vessel blockage in (very similar to people's the arteria coronaria)] long period do not produce thrombosis yet.In addition, adopting biodegradable chitosan is the coating material of medicine microspheres, and it can be degraded in human body.Simultaneously, do not produce the acidic materials that form when degrading as polylactic acid, the catabolite oligosaccharide of chitosan, nonirritant is owing to adopt the medicine microspheres sorption of medicine carrying to be attached on the mode in rack surface hole.When the microsphere degraded, behind the disengaging hole, this hole promptly becomes the ＂ foothold ＂ of normal endothelial tissue growth for this reason, helps the arteria coronaria endothelial tissue and climbs living, growth, thereby impel the rack surface blood vessel endotheliumization of inserting arteria coronaria.Complete rack surface blood vessel endotheliumization has just overcome the DES of current clinical use and since drug release intact after, polymer hinders the rack surface blood vessel endotheliumization as foreign body, forms the generation of thrombosis and the adherent bad phenomenon of support in (late period) support.
In a word, this utility model provides prevent the coronary endometrium excessive increase a kind of having, and the stable drug-eluting coronary artery stent that forms complete, normal arteria coronaria inner membrance coating.This newtype drug FirebirdTM has and is preventing coronary artery bracket postoperative thrombosis, cause outside the narrow once again function of early stage arteria coronaria, also have and to make the arteria coronaria inner membrance normally form complete tunica intima on the newtype drug FirebirdTM surface of inserting to coat, prevent coming off in late period owing to thrombosis that still has exposed rack surface to impel and support.
In addition, the medicine microspheres coating material of the art of this patent first-selection is a chitosan, and this is the nitrogenous natural organic-compound of quantity maximum beyond the isolating protein on the earth at nature next in number only to cellulosic material.Functions such as that itself just has is antibacterial, antiinflammatory are the more comprehensive biomaterials of kind of performance.Adopting the very high Biodegradable material of biological safety is capsule material, with the microspheres form drug loading, stick together band medicine microsphere with the ceramic surface absorption of support multi-hole, simultaneously climb life for the normal blood vessels endothelial tissue at the rack surface of inserting again at cushion, promote that series of advantages such as the support endothelialization creates conditions are the advantage and the original place of present patent application technical scheme.
Technology contents of the present utility model and technical characterstic the sixth of the twelve Earthly Branches disclose as above, yet the personage who is familiar with this technology still may do various replacement and the modifications that do not deviate from this case utility model spirit based on announcement of the present utility model.Therefore, protection domain of the present utility model should be not limited to those disclosed embodiments, and should comprise various do not deviate from replacement of the present utility model and modifications.
Claims (9)
1. a drug-eluting coronary artery stent includes matrix, it is characterized in that:
This drug-eluting coronary artery stent also includes compacted zone and weaker zone, and this compacted zone and weaker zone are distributed on the matrix successively.
2. drug-eluting coronary artery stent as claimed in claim 1 is characterized in that, this compacted zone is the metal oxide ceramic layer in fine and closely woven aperture.
3. drug-eluting coronary artery stent as claimed in claim 2 is characterized in that, this weaker zone is wide-aperture metal oxide ceramic layer.
4. as claim 2 or 3 described drug-eluting coronary artery stents, it is characterized in that, be equipped with medicine microspheres in the wide-aperture metal oxide ceramic layer of the metal oxide ceramic layer in described fine and closely woven aperture and weaker zone.
5. drug-eluting coronary artery stent as claimed in claim 4 is characterized in that described medicine microspheres includes medicine and coating material.
6. drug-eluting coronary artery stent as claimed in claim 5 is characterized in that this drug-eluting coronary artery stent also includes biodegradable layers.
7. drug-eluting coronary artery stent as claimed in claim 6 is characterized in that, described biodegradable layers covers a side or the number side of this drug-eluting coronary artery stent.
8. drug-eluting coronary artery stent as claimed in claim 6 is characterized in that, described biodegradable layers is the coating material layer.
9. drug-eluting coronary artery stent as claimed in claim 3 is characterized in that, described metal oxide ceramic layer is a honeycomb texture.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNU2007201907399U CN201194855Y (en) | 2007-12-12 | 2007-12-12 | Medicament elution coronary-artery stent |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNU2007201907399U CN201194855Y (en) | 2007-12-12 | 2007-12-12 | Medicament elution coronary-artery stent |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN201194855Y true CN201194855Y (en) | 2009-02-18 |
Family
ID=40414492
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNU2007201907399U Expired - Fee Related CN201194855Y (en) | 2007-12-12 | 2007-12-12 | Medicament elution coronary-artery stent |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN201194855Y (en) |
-
2007
- 2007-12-12 CN CNU2007201907399U patent/CN201194855Y/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Ma et al. | Paclitaxel/sirolimus combination coated drug-eluting stent: in vitro and in vivo drug release studies | |
| Indolfi et al. | Molecular mechanisms of in-stent restenosis and approach to therapy with eluting stents | |
| Hårdhammar et al. | Reduction in thrombotic events with heparin-coated Palmaz-Schatz stents in normal porcine coronary arteries | |
| CN101455863A (en) | Medicine eluting coronary stent | |
| CN105833358B (en) | Intracranial drug eluting stent system and preparation method thereof | |
| KR20040050915A (en) | Coating of stents for preventing restenosis | |
| KR20080073328A (en) | Controlled drug release composition and drug releasing medical device | |
| CN112704686B (en) | Preparation method of calcium phosphate-rapamycin composite medicine, preparation method of medicine coating balloon and medicine coating balloon | |
| CN106806948B (en) | Application of PI3K/mTOR dual inhibitor | |
| Sternberg et al. | Implant-associated local drug delivery systems based on biodegradable polymers: customized designs for different medical applications | |
| CN101264345A (en) | Degradable blood vessel stent drug-eluting capable of reducing incidence rate of advanced thrombus | |
| Zhang et al. | In vitro hemocompatibility and cytocompatibility of dexamethasone-eluting PLGA stent coatings | |
| CN101195048A (en) | Compound medicament washing bracket and method for preparing the same | |
| CN101007187B (en) | Preparation method of composite drug-eluting stent and its drug coated layer | |
| CN101081316A (en) | Novel medicine eluting supporting stand | |
| CN101279112A (en) | Intravascular stent with PLGA blend medicament eluting surface coating | |
| CN103110985A (en) | Biodegradable bracket with multiple drugs | |
| CN106310395A (en) | Composite drug-loading stent and preparation method thereof | |
| CN101513540A (en) | Drug-eluting coronary artery stent and method for preparing same | |
| CN107496998B (en) | Peripheral drug eluting stent and preparation and application thereof | |
| Adhami et al. | Drug loaded implantable devices to treat cardiovascular disease | |
| CN101513543A (en) | Encapsulation drug microsphere of medicament-eluting coronary artery stent and method for preparing same | |
| EP3520789B1 (en) | New use of amlexanox | |
| CN104524637A (en) | High-molecular biological ceramic composite nanometer particle biodegradable stent and manufacturing method thereof | |
| WO2024087925A1 (en) | Cobalt-chromium alloy stent and drug eluting stent |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C17 | Cessation of patent right | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20090218 Termination date: 20100112 |